Targeted therapy of the AKT kinase inhibits esophageal squamous cell carcinoma growth in vitro and in vivo
Authors:
Open Access
- 18 March 2019
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 145 (4) , 1007-1019
Abstract
Esophageal cancer, a leading cause of cancer death worldwide, is associated with abnormal activation of the AKT signaling pathway. Xanthohumol, a prenylated flavonoid tested in clinical trials, is reported to exert anti‐diabetes, anti‐inflammation and anticancer activities. However, the mechanisms underlying its chemopreventive or chemotherapeutic effects remain elusive. In the present study, we found that xanthohumol directly targeted AKT1/2 in esophageal squamous cell carcinoma (ESCC). Xanthohumol significantly inhibited the AKT kinase activity in an ATP competitive manner, which was confirmed in binding and computational docking models. KYSE70, 450 and 510 ESCC cell lines highly express AKT and knockdown of AKT1/2 suppressed proliferation of these cells. Treatment with xanthohumol inhibited ESCC cell growth and induced apoptosis and cell cycle arrest at the G1 phase. Xanthohumol also decreased expression of cyclin D1 and increased the levels of cleaved caspase‐3, ‐7 and ‐PARP as well as Bax, Bims and cytochrome c in ESCC cells by downregulating AKT signaling targets, including glycogen synthase kinase 3 beta (GSK3β), mammalian target of rapamycin, and ribosomal protein S6 (S6K). Furthermore, xanthohumol decreased tumor volume and weight in patient‐derived xenografts (PDXs) that highly expressed AKT, but had no effect on PDXs that exhibited low expression of AKT in vivo. Kinase array results showed that xanthohumol treatment decreased phosphorylated p27 expression in both ESCC cell lines and PDX models. Taken together, our data suggest that the inhibition of ESCC tumor growth with xanthohumol is caused by targeting AKT. These results provide good evidence for translation toward clinical trials with xanthohumol.Keywords
Funding Information
- National Institutes of Health (CA 196639, CA187027)
- National Natural Science Foundation of China (NSFC81672767, 81802875)
This publication has 43 references indexed in Scilit:
- Effects of Neoadjuvant 5-Fluorouracil and Cisplatin Therapy in Patients with Clinical Stage II/III Esophageal Squamous Cell CarcinomaAnticancer Research, 2018
- Preclinical Models of Prostate Cancer: Patient-Derived Xenografts, Organoids, and Other Explant ModelsCold Spring Harbor Perspectives in Medicine, 2018
- A perspective on AKT 25-plus years after its discoveryScience Signaling, 2017
- Cancer incidence and mortality: A cohort study in China, 2008–2013International Journal of Cancer, 2017
- Significance of PI3K/AKT signaling pathway in metastasis of esophageal squamous cell carcinoma and its potential as a target for anti-metastasis therapyOncotarget, 2017
- The Chemopreventive Effect of the Dietary Compound Kaempferol on the MCF-7 Human Breast Cancer Cell Line Is Dependent on Inhibition of Glucose Cellular UptakeNutrition and Cancer, 2015
- The radio-sensitizing effect of xanthohumol is mediated by STAT3 and EGFR suppression in doxorubicin-resistant MCF-7 human breast cancer cellsBiochimica et Biophysica Acta (BBA) - General Subjects, 2013
- PI3K and Akt as molecular targets for cancer therapy: current clinical outcomesActa Pharmacologica Sinica, 2012
- Phosphorylation of p27Kip1 at Threonine 198 by p90 Ribosomal Protein S6 Kinases Promotes Its Binding to 14-3-3 and Cytoplasmic LocalizationJournal of Biological Chemistry, 2003
- Cell cycle dependent expression and stability of the nuclear protein detected by Ki‐67 antibody in HL‐60 cellsCell Proliferation, 1992